Stay updated on Durvalumab + Tremelimumab in Head and Neck Cancer Clinical Trial
Sign up to get notified when there's something new on the Durvalumab + Tremelimumab in Head and Neck Cancer Clinical Trial page.

Latest updates to the Durvalumab + Tremelimumab in Head and Neck Cancer Clinical Trial page
- ChecktodayNo Change Detected
- Check8 days agoChange DetectedThe page now shows Revision: v3.6.3, replacing the previous Revision: v3.6.2. This indicates a minor update to the page's version or template without altering study data.SummaryDifference0.0%

- Check14 days agoChange DetectedThe page's revision label was updated from v3.6.0 to v3.6.2, signaling a software release update. This change appears to be an internal maintenance update rather than a modification to the study content.SummaryDifference0.0%

- Check29 days agoChange DetectedEnrollment status updated to 'No longer looking for participants', indicating the study is not actively enrolling. New help/navigation sections (How to Read a Study Record, Common Questions, How to Join a Study) were added, and the Intervention/Treatment heading was updated from 'Intervention / Treatment' with an accompanying Revision: v3.6.0 tag.SummaryDifference0.4%

- Check36 days agoChange DetectedThe page revision was updated from v3.5.4 to v3.5.5. This indicates a minor behind-the-scenes update to the page without changing study information.SummaryDifference0.0%

- Check57 days agoChange DetectedThe page now shows a newer revision tag, Revision: v3.5.4, replacing Revision: v3.5.3. This signals a small backend or QC update to the page rather than a change to the study information.SummaryDifference0.0%

- Check72 days agoChange DetectedThe revision label on the page changed from v3.5.2 to v3.5.3, indicating a software update to the page. It updates the version identifier displayed to users.SummaryDifference0.0%

Stay in the know with updates to Durvalumab + Tremelimumab in Head and Neck Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab + Tremelimumab in Head and Neck Cancer Clinical Trial page.